Summary Leucocyte counts of < 5´10
Introduction
The use of leucocyte-depleted blood products has been shown to reduce, or prevent, adverse transfusion reactions, transfusion-related bacterial sepsis, febrile reactions, HLA antigen alloimmunization and transmission of viruses such as cytomegalovirus (CMV) (Wenz et al., 1980; Sniecinski et al., 1988; De Graan-Hentzen et al., 1989; Orlin & Ellis, 1997; Raife, 1997; Wagner, 1997) . Furthermore, the emergence of variant Creutzfeldt±Jakob Disease (vCJD) in the United Kingdom , coupled with increasing evidence that the distribution of this disease in human tissue may be different to that of the classical form of CJD (Hill et al., 1999) , has raised questions regarding the safety of UK plasma products (Ludlam, 1997) .
Recent guidelines suggest that blood product units should have less than 5´10 8 leucocytes in order to prevent febrile transfusion reactions (Venglen-Tyler, 1996) and fewer than 5´10 6 to prevent alloimmunization and the transmission of cytomegalovirus (Venglen-Tyler, 1996 ; British Committee for Standards in Haematology 1998). The latter level has recently been adopted by the UK Transfusion Services and all issued blood components are required to have leucocyte counts of < 5´10 6 in 99% of components, with 95% statistical con®dence. The expansion in production of leucocytedepleted blood products has therefore increased the requirement for reliable and robust validation processes and quality control measures both at internal and external level.
The enumeration of leucocytes in peripheral blood samples is routinely achieved using automated leucocyte counters. However, the detection level required for monitoring leucocyte depletion, i.e. < 0.1´10 9 /l, is below the sensitivity of routine haematology analysers. Alternative methods are required and currently include the Nageotte counting chamber, volumetric capillary cytometry and¯ow cytometry (Conte et al., 1997 ; BEST working Party of the International Society of Blood Transfusion 1996). Flow cytometry has been the method of choice, particularly as large numbers of samples can be processed routinely. Absolute cell subset counting by single platform¯ow cytometry has been shown to reduce the interlaboratory variation for CD4 + T lymphocyte and CD34 + stem cell counting (Strauss et al., 1996; Barnett et al., 1999) and the approach has been recommended for low level leucocyte counting (Conte et al., 1997) . The decision by the government health departments to leucocyte deplete all blood components, prompted UK NEQAS for Leucocyte Immunophenotyping, in conjunction with the UK Transfusion Services, to initiate an external quality assessment (EQA) program for low level leucocyte counting, using blood products stabilized using a previously described whole blood process . In this report, we present data demonstrating that such an approach can be used to provide a valuable national/international low-level leucocyte counting EQA scheme.
Materials and methods
Leucocytes obtained following leucopheresis of a leukaemia patient were stabilized and then added by limiting dilution to stabilized leucocyte-depleted whole blood, or pooled platelet products, to achieve a ®nal concentration range of 0±70 cells/ll. These materials are stable for up to two years at 4°C Eighteen UK National Blood Service Centres were issued with six 2 ml samples of stabilized blood each month (three peripheral blood and three pooled platelet). Each centre was required to determine the absolute leucocyte count for each sample using their routine analyser (e.g. ow cytometry, volumetric scanning¯ow cytometry (IMAGN 2000) and/or the Nageotte chamber). A nominal volume was provided with each specimen (re¯ecting the donor volume postleucocyte depletion) to enable the total number of leucocytes in the original blood product to be calculated. Participating centres were required to state if the unit met the criteria of < 5´10 6 leucocytes per unit blood product (BCSH 1998) and whether therefore it was suitable for release. Two staining techniques were used, the LeucoCOUNT TM staining system (Becton Dickinson BioSciences, San Jose, USA) and a nonstandardized propidium iodide (PI) method, prepared according to local protocols. All data was returned to UK NEQAS within two weeks of specimen issue and detailed statistical analysis undertaken using in-house software (Visual dBASE, Borland International Inc., CA, USA).
Results
A total of 600 complete data sets for the blood and platelet from 24 samples were returned from the 18 participating centres (Tables 1 and 2 ). Inter-laboratory coef®cients of variation (CV) were dependent on sample type (Tables 3  and 4 ) and leucocyte count. For example, samples with leucocyte counts < 1 cell/ll gave interlaboratory CVs > 100%. However, within the approximate critical range of 5±30 cells/ll (equating to blood products with leucocyte counts < 5´10 6 /l depending on blood volume) the mean CVs were lower, ranging from 4.8 to 35.7%. The manual Nageotte method resulted in consistently higher interlaboratory CVs for all samples, except for P10 that
The EQA of low level leucocyte counting in blood transfusion products All values expressed as cells/ll. had the highest count (Table 4) . If the 75th and 25th centiles for each sample (see Tables 3 and 4 ) are taken to indicate the upper and lower limits of acceptability for the median value for a given technique, then the¯ow cytometric and IMAGN 2000 systems had fewer outlying results (2) when compared to the Nageotte method (15). The IMAGN 2000 had the lowest CVs for samples with counts of 5±30 cells/ll (range 7.5±36%, mean 16.7) when compared to the¯ow cytometric (range 13.8±88%, mean 29.5) and Nageotte methods (range 20.6±117%, mean 61.8). However, in the four whole blood specimens where the count was < 5 cells/ll the interlaboratory CV for the IMAGN 2000 system was higher than¯ow cytometry in three specimens (Table 3) . Conversely, in the 4/5 platelet samples issued with leucocyte counts of < 5 cells/ll the interlaboratory CVs for the IMAGN 2000 system were lower than¯ow cytometry. During the study, the number of centres using a nonstandard PI staining approach fell such that only two centres continued to use`in-house' methods after the sixth issue. The ®rst ®ve issues revealed an interlaboratory variation of between 6.7 and 30.4% for the Leuco-COUNT TM method compared to 3.3±63.2% for the PI method. Using the 75th and 25th centiles to de®ne the limits of acceptability for the median value for a given method (Tables 5 and 6 ), it was noted that all the LeucoCOUNT TM results were satisfactory, whilst the PI method gave unsatisfactory results for ®ve platelet (P3, P9±12) and two whole blood samples (R3±4).
A number of gating strategies were noted (Figures 1±3). Site A, for example, employed the simplest approach, utilizing only two histograms, whilst site C used seven histograms, incorporating a time vs.¯uorescence parameter, in order to monitor laser performance during acquisition. The placement of regional gates was also noted to vary. Site B used a large analysis region, encompassing leucocytes and possible debris, whilst site C used a restricted gate placement, thereby excluding a number of leucocyte events (Figure 3 , region f). All centres differed in their de®nition of the bead population, with the result that doublet and quadruplet populations were either included or excluded in the ®nal analysis.
For each issue, the number of centres reporting for a given sample as`out of consensus' and which would theoretically have led to an inappropriately released unit was: sample R1 (one centre), sample R2 (®ve centres), sample R5 (two centres) and sample R6 (three centres), and for platelet preparations: sample P3 (six centres), sample P4 (two centres), sample P5 (four centres), sample P6 (four centres) and sample P12 (one centre). There was one laboratory (sample P8) that failed the unit when the consensus was that the unit met the BCSH criteria. Further detailed analysis identi®ed that one centre consistently passed all the whole blood samples and one platelet sample while another passed all the platelet samples when the consensus was a fail. The centre that failed the platelet unit when the consensus was a pass used the Nageotte counting method. 
Discussion
The decision by the UK Government to implement a leucocyte depletion policy for blood components prompted UK NEQAS for Leucocyte Immunophenotyping, in collaboration with the UK Transfusion Services, to introduce an EQA scheme for low-level leucocyte counting in 1999.
Stabilized whole blood and platelet samples, containing different leucocyte counts, were issued to Blood Transfusion Centres to facilitate their validation processes for leucocyte depletion. Such an approach has been previously documented to eliminate variability due to specimen degradation and to provide sample integrity for over 600 days (Barnett et al., , 1999 . It is now well recognized that low level absolute leucocyte counting, particularly for CD4 + T lymphocytes and CD34 + peripheral blood stem cells, is best performed using the`single-platform'¯ow cytometric method (Connelly et al., 1995; Strauss et al., 1996; Barnett et al., 1999; Reimann et al., 2000; Schnizlein-Bick et al., 2000 1 ). This is because the`dual-platform' approach has to rely upon the white cell count (WCC) generated by haematology analysers, a factor that contributes to a high CV (Robinson et al., 1992; Barnett et al., 1999) . Furthermore, n/a 1 n/a n/a P8 11 0 0.15 0.4 267 2 n/a 0 n/a n/a P9 11 1.5 1.7 2 29.4 2 n/a 1 n/a n/a P10 11 62 65.9 70 12.1 2 n/a 76.5 n/a n/a P11 11 0 0.4 0.5 125 2 n/a 1.5 n/a n/a P12 11 17 19 20.5 18.4 2 n/a 23.5 n/a n/a All absolute counts expressed as cells/ll. n/a, not applicable (statistically invalid); ICV, inter-laboratory coef®cient of variation. 11 7.8 9 10 25 2 n/a 8.5 n/a n/a R8 11 0.8 1.1 1.7 80.9 2 n/a 1 n/a n/a R9 11 2 3 3.1 36.7 2 n/a 3 n/a n/a R10 11 1 1 1.6 58.4 2 n/a 1.5 n/a n/a R11 11 7 10.5 13 56.9 2 n/a 12.5 n/a n/a R12 11 4 6 7.6 60 2 n/a 7 n/a n/a All absolute counts expressed as cells/ll. n/a, not applicable (statistically invalid); ICV, inter-laboratory coef®cient of variation.
haematology analysers cannot be reliably used for the enumeration of leucocytes in leucocyte-depleted blood components, as the levels are below their detection limit. The Nageotte counting method has been routinely employed to circumvent these problems although it is laborious and time-consuming (Szu¯ad & Dzik 1997) . As a result of these problems, single platform¯ow cytometry has become the method of choice. However, Conte et al., (1997) suggested that the use of a method that can count to extremely low levels of leucocytes also increases the likelihood of underestimating the leucocyte content in post®ltration blood components. Furthermore, Rebulla & Dzik (1994) reported, using blood that was less than 24-hold, that¯ow cytometry and the Nageotte method were The EQA of low level leucocyte counting in blood transfusion products equal on performance at levels above 1 cell/ll but¯ow cytometry showed less variability at levels below this value. We present data, resulting from the issue of 24 samples to 18 laboratories, that reveals a wide range of interlaboratory CVs. However, within the critical range of approximately 5±30 cells/ll depending on blood volume, which equates approximately to blood components with leucocyte counts of < 5´10 6 (BCSH, 1998), the CVs improved, although still ranged from 4.8 to 35.7%. Analysis by technique showed the IMAGN 2000 approach to have the lowest overall CV, whilst the Nageotte had the greatest variation in this critical range. However, the interlaboratory CV of the IMAGN system was higher than ow cytometry in the majority of whole blood specimens when the leucocyte count was < 5 cells/ll. This ®nding may re¯ect the way in which the IMAGN 2000 system differentiates positive and negative¯uorescence peaks and the fact that red cells in the whole blood samples results in higher`background' noise which may produce increased variability for the¯ow cytometric methods. The wide range of CVs with the Nageotte supports the ®ndings of the Biomedical Excellence for Safer Transfusion International Working Party (BEST, 1996) that studied the variation between seven sites using a modi®ed Nageotte method. In an attempt to improve the reproducibility of the technique, this study required a 20-fold concentration of leucocytes prior to analysis. Nevertheless, CVs of < 50% were still reported when cells counts were equivalent to 10 cells/ll. Furthermore, Conte et al., (1997) compared¯ow cytometry with the modi®ed Nageotte method and reported that the Nageotte yielded a one log higher value. They also found a difference in the post®ltration leucocyte content, and suggested that the cell loss related to the method employed and the various technical manipulations involved. Interestingly, we have previously shown that interlaboratory CVs are improved if minimal sample manipulation is undertaken, particularly in rare event analysis, such as CD34 + stem cell enumeration (Barnett et al., , 1999 . We also found that the IMAGN 2000 system gave lower mean interlaboratory CVs than the¯ow cytometric methods. This probably re¯ects the fact that the IMAGN 2000 is a closed system, using preprogrammed software to identify rare cell events, whereas the¯ow cytometric approach is more operator dependent. However, this variation increases for the IMAGN 2000 at cell concentrations of < 5 cells/ll particularly when red cells are present. This study has highlighted a number of additional factors that may lead to variation of results. Firstly, there was no consensus regarding the use of histograms or gating strategies. One laboratory, for example, used a twohistogram approach whereas another employed seven histograms for leucocyte enumeration. Secondly, signi®-cant variability existed with regard to analysis region placement, with one centre excluding some leucocyte events as the result of inappropriate gate placement. Recently, the National Blood Authority for England has introduced a standardized national protocol for those laboratories using¯ow cytometric methods. Studies are underway to evaluate if the use of such an approach will result in an improvement in interlaboratory CVs. Finally, laboratories using commercial nuclear stains (Leuco-COUNT TM ) had consistently lower CVs than those using in-house' propidium iodide staining methods. The former is a standardized staining kit that incorporates speci®cally designed software analysis, using a single platform beadbased method and a standardized nucleic acid staining reagent, whereas the propidium method is not only nonstandardized but also relies on a user-de®ned gating strategy. Such variability clearly in¯uenced the decision of individual sites on whether the blood components met UK recommendations for the number of leucocytes permitted in blood transfusion products (BCSH, 1998) . However, we noted that upon introduction of a standardized protocol the number of laboratories out of consensus was signi®-cantly reduced.
In conclusion, this study highlights the current variability in low level leucocyte counting, especially within the critical range of 5±30 cells/ll. The Nageotte approach, for example, gave the highest interlaboratory CVs, whereas the IMAGN 2000 produced the lowest CVs. Furthermore, the use of nonstandardized nuclear staining reagents resulted in higher CVs than the LeucoCOUNT TM method. As a result, we would recommend that a standardized protocol (incorporating targeted training) and nuclear staining reagent be employed for the routine validation of leucocyte-depleted blood components. Such an approach has been successfully used on an international basis to obtain interlaboratory CVs of < 10% for the enumeration of CD34 + stem cells (Barnett et al., 2000) . Finally, we demonstrate that stabilized blood preparations can be successfully used to provide a national/international low-level leucocyte counting scheme.
